

MOUSTAFA NASSAR

# Gene Therapy in Glaucoma 13-13

MOUSTAFA NASSAR

Prof and Head of Oph dept- Menofyia Univ and Secretary General of ESG



#### Genetics is the science of heredity. Gr. genesis = origin

Thanks to J. Craig Venter who successfully mapped the human genetic code and gained a worldwide recognition in year 2000, thus paved a path to gene therapy.



ESG


### Let's start the "gene" story from its **"tail"**

In summary:


In the human genome, each cell nucleus contains 46 chromosomes


22 pairs of autosomes

A single pair of sex chromosomes XX or XY



The DNA of these chromosomes has a double helix Attached to it, the base pair of amino acids





Inside each cell nucleus there, are 46 chromosomes that carry 100,000 genes

The "gene" is the functional unit of hereditary, that occupies a specific place (locus) on a chromosome and it direct the formation of protein.

This protein determine the function of each cell.



Only 0.1% is responsible for all the changes in human features,shapes,color, or behavior


Moustafa Nassar



When a copy is read, i.e. on reading gene information, this is called " gene expression". The gained knowledge is in the form of protein synthesized for different body cell functions.

Gene expression Transcription
Translation







Cells can be totally different, both structurally and functionally, despite the fact that all carry the same genetic information (46 chromosomes). This means that


Inside each cell there is a large big libarary.





ESG A simple blood sample or buccal screening can give all the information about the eye, kidney, or any other body organ. This is because all of them carry the same genetic information or the same big library.





The **TIGR/MYOC gene** (trabecular meshwork glucocorticoid response/ Mycoline) is the gene whose mutation is strongly suggested to be responsible for glaucoma.

Mutation in **TIGR** were identified in juvenile glaucoma families and found to affect 3% of the general glaucoma patients.

Mutation of this gene can produce abnormal gene expression. This consequently affects the TM nature by changing the cytoskeleton or the internal structure of TM resulting in glaucoma.




Human Genome Organization (HUGO/GDC) uses GLC as the general symbol for glaucoma.


<u>The numbers 1,2, and 3 represent</u> open angle, angle closure, and congenital glaucoma respectively. These are followed by "<u>alphabetical letters</u>" arranged in order according to the discovered gene in chronological order.


> GLC1A = 1<sup>st</sup> gene to be discovered GLC1F = 5<sup>th</sup> gene to be discovered Moustafa Nassar


This is an example of Gene: CFTR ESG


Chromosomal location of this agene 7 q 3 1 - 2














## Genetics and Glaucoma Therapy



The medical treatment will be replaced by gene therapy



The current treatment which is now restricted to lowering IOP, may be guided by the knowledge of each person's genotype.


- Patients with **GLC1A** gene defect may respond best with **surgery**
- Medical treatment is effective in GLC1C, GLC1D and GLC1F gene
- Individuals with mutation of GLC1B or GLC1E (NTG) may require treatment of ON perfusion.



Moustafa Nassar

<u>Future traditional treatment</u>, will include both pharmacological and gene therapy, targeting ciliary epithelium and TM <u>via topical or intracameral</u> <u>injection of adenovirus vectors</u>.

Stromelysin is a pharmacological drug that bypass a gene defect in glaucoma.








# Genetic therapy of glaucoma

simulate transplantation surgery, i.e removal of mutant gene and replace it with a normal one.










The gene\* of interest-is carried\* by a viral vector to be-introduced \*into the nucleus of the TM cell by a process called\* endocytosis.-This restores \*the mutant gene to a normal one\* Thus-normal gene expression with a normal mRNA and- protein production would be expected. Massar

#### 2.Non-viral vector therapy:

Have more <u>immediate potential</u> and greater versatility and may be more accepted.

<u>They can</u> either <u>replace</u> defective genes, <u>inhibit</u> transcription, <u>correct</u> mutant m-RNA, or <u>directly replace</u> <u>needed protein.</u>





### Gene therapy in glaucoma

Gene therapy can replace or inactivate defective genes.

so as to help "<u>individuals at risk of</u> <u>developing glaucoma</u> " before irreversible damage to the optic nerve takes place.





